Biotech Pharmaceutical
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynConr vaccines are designed to generate universal responses against multiple unmatched strains of pathogens. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. 4/8/15 - A federal agency has selected Inovio Pharmaceuticals Inc. to lead an effort to develop multiple treatment and prevention approaches against Ebola. The effort is being funded through a $45 million grant from the Defense Advanced Research Projects Agency, an agency of the Department of Defense